GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Phibro Animal Health Corp (NAS:PAHC) » Definitions » Operating Income

Phibro Animal Health (Phibro Animal Health) Operating Income : $57.3 Mil (TTM As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Phibro Animal Health Operating Income?

Phibro Animal Health's Operating Income for the three months ended in Dec. 2023 was $15.7 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $57.3 Mil.

Warning Sign:

Phibro Animal Health Corp has recorded a loss in operating income at least once over the past 3 years.

Operating Margin % is calculated as Operating Income divided by its Revenue. Phibro Animal Health's Operating Income for the three months ended in Dec. 2023 was $15.7 Mil. Phibro Animal Health's Revenue for the three months ended in Dec. 2023 was $249.9 Mil. Therefore, Phibro Animal Health's Operating Margin % for the quarter that ended in Dec. 2023 was 6.28%.

Warning Sign:

Phibro Animal Health Corp operating margin has been in a 5-year decline. The average rate of decline per year is -8.2%.

Phibro Animal Health's 5-Year average Growth Rate for Operating Margin % was -8.20% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Phibro Animal Health's annualized ROC % for the quarter that ended in Dec. 2023 was 2.89%. Phibro Animal Health's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 6.19%.


Phibro Animal Health Operating Income Historical Data

The historical data trend for Phibro Animal Health's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phibro Animal Health Operating Income Chart

Phibro Animal Health Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 83.23 69.19 74.87 78.99 71.85

Phibro Animal Health Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.84 18.55 23.77 -0.73 15.70

Phibro Animal Health Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $57.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Phibro Animal Health  (NAS:PAHC) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Phibro Animal Health's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=62.804 * ( 1 - 64.26% )/( (777.856 + 773.848)/ 2 )
=22.4461496/775.852
=2.89 %

where

Invested Capital(Q: Sep. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=964.523 - 95.514 - ( 91.153 - max(0, 172.355 - 584.424+91.153))
=777.856

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=972.708 - 106.367 - ( 92.493 - max(0, 187.735 - 586.586+92.493))
=773.848

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Phibro Animal Health's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=35.9/( ( (229.679 + max(351.518, 0)) + (238.998 + max(339.406, 0)) )/ 2 )
=35.9/( ( 581.197 + 578.404 )/ 2 )
=35.9/579.8005
=6.19 %

where Working Capital is:

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(149.228 + 279.154 + 64.889) - (95.514 + 0 + 46.239)
=351.518

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(150.627 + 286.68 + 56.786) - (106.367 + 0 + 48.32)
=339.406

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Phibro Animal Health's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=15.701/249.943
=6.28 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Phibro Animal Health Operating Income Related Terms

Thank you for viewing the detailed overview of Phibro Animal Health's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Phibro Animal Health (Phibro Animal Health) Business Description

Traded in Other Exchanges
Address
300 Frank W. Burr Boulevard, Suite 21, 3rd Floor, Glenpointe Centre East, Teaneck, NJ, USA, 07666-6712
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
Executives
Judith Weinstein officer: See Remarks C/O PHIBRO ANIMAL HEALTH CORP, 300 FRANK W. BURR BOULEVARD, STE 21, TEANECK NJ 07666
Alejandro Bernal director C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
E Thomas Corcoran director
Larry Lee Miller officer: Chief Operating Officer 8 HAZELWOOD COURT, WARREN NJ 07059
Damian Finio officer: Chief Financial Officer C/O IGI LABORATORIES, INC., 105 LINCOLN AVENUE, BUENA NJ 08310
Robin Aukerman officer: President,North America Region C/O PHIBRO, GLENPOINTE CENTRE EAST, 3RD FL, 300 FRANK W. BURR BLVD, STE 21, TEANECK NJ 07666
Daniel M Bendheim director, officer: Exec. VP, Corporate Strategy 300 FRANK W. BURR BOULEVARD, SUITE 21, TEANECK NJ 07666
Dean J Warras officer: Pres Animal Health & Nutr N.A. 5113 SPYGLASS HILL, QUINCY IL 62305
Jack Bendheim director, 10 percent owner, officer: President and CEO C/O EMPIRE RESOURCES, INC., 1 PARKER PLAZA, SUIET 10, FORT LEE NJ 07024
Bfi Co., Llc 10 percent owner 300 FRANK W. BURR BLVD., STE 21, TEANECK NJ 07666
Jonathan Bendheim director GLENPOINTE CENTRE EAST, 3RD FLOOR, 300 FRANK W. BURR BLVD. SUITE 21, TEANECK NJ 07666
Anthony Andolino officer: SEE REMARKS GLENPOINTE CENTRE EAST, 3RD FLOOR, 300 FRANK W. BURR BLVD., STE 21, TEANECK NJ 07666
Richard G Johnson officer: Chief Financial Officer 7 WEST 96TH STREET, APT. 11C, NEW YORK NY 10025
Gerald K Carlson director 2496 OLD BEACH ROAD, WAYZATA MN 55391
Thomas G Dagger officer: SVP, Gen Counsel and Corp Sec 41 WILCOX DRIVE, MOUNTAIN LAKES NJ 07046